Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oxytocin · 2 trials · 3 indications
Changes in code substitution scores as measured by the Defense Automated Neurobehavioral Assessment (DANA). Data will be measured in milliseconds for response time.
Changes in choice reaction time scores as measured by the Defense Automated Neurobehavioral Assessment (DANA). Data will be measured in milliseconds for response time.
Altered ocular response as measured by the I-Portal Portable Assessment System (i-PAS). Saccades will be monitored and counted throughout the duration of the assessment.
Altered ocular response as measured by the I-Portal Portable Assessment System (i-PAS). Number of blinks will be counted through the course of the assessment.
Altered ocular response in blink duration as measured by the I-Portal Portable Assessment System (i-PAS). Blink duration will be measured in milliseconds.
Change in muscle glutathione reductase enzyme activity assessed by measuring muscle tissue levels of the reduced product, glutathione (GSH)
Change in blood glutathione reductase enzyme activity assessed by measuring blood levels of the reduced product, glutathione (GSH)
| Arm | Type | Description |
|---|---|---|
| Oxytocin Nasal Spray | EXPERIMENTAL | Single dose of intranasal oxytocin (48 IU) prior to testing protocol. |
| Placebo Nasal Spray | PLACEBO_COMPARATOR | Single dose of intranasal treatment with placebo (identical to oxytocin nose spray minus the oxytocin) |
| Name | Type | Description |
|---|---|---|
| Oxytocin nasal spray | DRUG | Intranasal treatment with oxytocin via nasal spray (48 IU per dose) |
| Placebo nasal spray | DRUG | Intranasal treatment with placebo via nasal spray |
Inclusion Criteria: * Recreationally skilled swimmers Exclusion Criteria: * Smoking/vaping, a history of psychiatric disorders, safety requirements related to the oxytocin administration \[hypersensitivity to oxytocin or vasopressin, history of hyponatremia, syndrome of inappropriate antidiuretic...
Oxytocin is being studied for use in oxidative stress, inflammation, and cold exposure. It is an investigational small molecule in Phase 2 clinical development, evaluated in healthy male volunteers in the United States.
Oxytocin is being developed by Cognition Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker CGTX. The company is conducting clinical trials to evaluate the drug's effects on oxidative stress, inflammation, and cold exposure.
Oxytocin is in Phase 2 clinical development. It has completed two Phase 2 trials, one for oxidative stress and inflammation and another for cold exposure. The drug is investigational and not yet approved for any use.
Oxytocin has completed two Phase 2 trials. NCT04732247 studied oxidative stress and inflammation in 40 participants, and NCT04738838 studied cold water task performance and recovery in 17 participants. Both were randomized, double-blind, placebo-controlled trials in healthy male volunteers in the United States.
Oxytocin is a small molecule being developed by Cognition Therapeutics, Inc. for oxidative stress and cold exposure. It is distinct from other uses of oxytocin, such as labor induction, and is being investigated for different indications in clinical trials.